Motugivatrep eye drops for dry eye disease launch in Japan

A new eye drop called motugivatrep ophthalmic suspension 0.3% (Avarept) has been released in Japan to treat dry eye disease (DED), as announced by Senju Pharmaceutical. The approval and availability of this product introduce a new way to target the nerve pathways in the eye that cause discomfort.

The launch is supported by results from a phase 3 randomized, double-masked, placebo-controlled trial (3-02), which met its primary endpoint of improving patient-reported symptom burden as measured by the Dry Eye-Related Quality-of-Life Score (DEQS). While the sponsor emphasized improvements in subjective symptoms, limited publicly available data constrain full assessment of objective ocular surface outcomes and safety signals.

Trial and regulatory overview

The pivotal phase 3 trial enrolled patients with DED and evaluated motugivatrep against placebo over a parallel-group design. The primary endpoint was change in DEQS, a validated 15-item patient-reported outcome instrument assessing symptom severity and functional impairment. According to the press release, the study demonstrated a statistically significant improvement in DEQS scores.

However, detailed efficacy data—including magnitude of effect, secondary endpoints (eg, corneal staining, tear breakup time), and subgroup analyses—have not yet been published in a peer-reviewed journal. Similarly, safety outcomes were not disclosed in detail, limiting comparative interpretation against existing therapies.

Japan’s regulatory decision reflects a continued openness to therapies demonstrating patient-reported benefit in DED, a condition in which symptom–sign discordance is well recognized.¹

Clinical context

DED is a multifactorial disorder of the ocular surface characterized by tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities.¹ The condition affects an estimated 5% to 50% of the global population depending on diagnostic criteria, with increasing prevalence linked to aging, digital device use, and environmental factors.¹

Current treatment options include artificial tears, topical anti-inflammatory agents such as cyclosporine and lifitegrast, and short-term corticosteroids. Cyclosporine (eg, Restasis, Cequa) targets T-cell–mediated inflammation, while lifitegrast (Xiidra) inhibits lymphocyte function–associated antigen-1 (LFA-1).²,³ These agents primarily address inflammatory pathways but may have delayed onset of action and variable tolerability.

The introduction of a TRPV1 antagonist reflects growing recognition of neurosensory dysregulation in DED pathophysiology. TRPV1 channels, expressed on corneal nociceptors, are activated by heat, hyperosmolarity, and inflammatory mediators, contributing to pain and discomfort.⁴ Targeting this pathway may offer a more direct approach to symptom relief.

Drug background and mechanism

Motugivatrep is a selective TRPV1 antagonist designed for topical ophthalmic use. By inhibiting TRPV1 activation, the drug is hypothesized to reduce corneal nerve hypersensitivity and downstream discomfort signals associated with tear film instability.

To date, no TRPV1-targeted therapies have been approved for DED in major markets, making this the first reported regulatory approval of its class. Prior research has explored TRPV1 modulation in ocular pain and inflammation, but clinical translation has been limited.⁴

Interpretation and clinical implications

The availability of motugivatrep introduces a mechanistically distinct option for DED, particularly for patients whose primary burden is symptomatic discomfort rather than overt ocular surface damage. However, several uncertainties remain.

First, the absence of published data limits evaluation of effect size and clinical relevance. Improvements in patient-reported outcomes are important, but without corroborating objective signs, it remains unclear how the therapy compares with existing anti-inflammatory treatments.

Second, safety considerations—including potential effects on corneal sensitivity or epithelial integrity—require further scrutiny, particularly given the role of TRPV1 in protective nociception.

Finally, the generalizability of findings beyond the Japanese population and regulatory context is uncertain. Additional studies and regulatory submissions in other regions will likely clarify the therapy’s broader role.

Limitations and next steps

Key limitations include the lack of peer-reviewed publication of phase 3 results and absence of detailed safety data in the public domain. Head-to-head comparisons with established therapies have not been reported.

Future directions include confirmatory trials, real-world evidence generation, and exploration of combination approaches targeting both inflammatory and neurosensory pathways. Regulatory review outside Japan will also be critical to determining global adoption.

References

1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276-283.
   https://www.sciencedirect.com/science/article/pii/S1542012417301076

2. Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475-483.
   https://www.sciencedirect.com/science/article/pii/S0161642013011504

3. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate to severe dry eye disease. Ophthalmology. 2000;107(5):967-974.
   https://www.sciencedirect.com/science/article/pii/S0161642000001217

4. Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15(3):404-437.
   https://www.sciencedirect.com/science/article/pii/S1542012417301106